HEARTBEAT-TROP. Polyethylene Glycol Precipitation to Unmask Macrotroponin

NCT07726420 · tracked via the Priya Life Science Germany tracker

Sponsor

Technical University of Munich

Phase

Not applicable

Started

2026-07-15

Last updated

2026-07-24

Condition(s) studied

Diagnoses Disease

Investigational drug(s) / intervention(s)

Polyethylene glycol precipitationTransthoracic echocardiography

Polyethylene glycol precipitation: PEG will be assessed in patients with acute coronary syndrome upon presentation and before hospital discharge. Athletes will receive this intervention at baseline and within one hour after completion of the marathon

Transthoracic echocardiography: Patients with acute coronary syndrome will receive echocardiography upon presentation and before hospital discharge. Athletes will receive echocardiography at baseline and within one after marathon completion.

Study summary

Troponin elevation can, among others, be due to myocardial infarction, acute inflammation or structural heart disease. Formation of macrocomplexes against troponin is an underestimated cause for persistent troponin elevation. Polyethlylene glycol precipitation (PEG) can differentiate macrotroponin from real troponin elevation, but cut-off values for PEG have not been established. PEG is analyzed in patients with acute coronary syndrome undergoing invasive coronary angiography and compared to healthy marathon runners who have undergone cardiological pre-participation screening and have rested for 24 hours.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Age above 18 years * Group with acute coronary syndrome (ACS): Diagnosis of ACS (ST-segment elevation or non-ST-segment elevation myocardial infarction according to the European Society of Cardiology Guidelines 2023 with at least one measurement of high sensitive troponin I or T above the 99th percentile of reference). * Marathon runners: Participation in a marathon following cardiological pre-participation screening and medical clearance for competition. No clinical signs of cardiovascular or structural heart disease Exclusion Criteria: * Patients with acute coronary syndrome: Known macrotroponin, terminal renal disease (glomerular filtration rate below 10ml per minute), diagnosis of cancer, pregnancy * Marathon runners: Coronary artery disease, structural heart disease, diagnosis of cancer, pregnancy

Primary outcome measure(s)

Recovery of troponin after polyethylene glycole precipitation in health and disease — Day 1
Comparison of polyethylene glycol recovery in athletes at rest and patients during acute coronary syndrome

Trial sites (1)

Facility	City	Region	Status
Technical University Munich	Munich	Bavaria	Recruiting

More Technical University of Munich trials in Germany

Blood Flow Restriction Training For The Treatment Of Lateral Epicondylopathy Recruiting

Prehabilitation in Childhood Soft Tissue or Bone Sarcomas Active, not recruiting

LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) Recruiting

Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy Recruiting

Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07726420 on ClinicalTrials.gov ↗ ← All trials in Germany